The World's First Clinical Base Edting Therapy for Hemoglobinopathy

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

CorrectSequence-Ther

More Like This

PR Newswire associated0

High-Precision Base Editing Clinical Treatment for Sickle Cell Disease -- CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient

High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease

PR Newswire associated0

The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Exciting Progress | Gritgen Therapeutics Completed Patients Enrollment in China’s First Gene Therapy Investigator-Initiated Trial for Hemophilia A and also Achieved the First Patient Dosed in China Phase I Trial in Patients with Severe Hemophilia A

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia